BioTime, Inc. , a biotechnology company that develops and markets products in the field of regenerative medicine, today announced it has submitted a Clinical Investigation Protocol to European regulatory authorities for approval to initiate studies for its Renevia stem cell delivery platform.
http://www.laboratorynetwork.com/doc.mvc/biotime-submits-human-clinical-trials-renevia-europe-0001?atc~c=771+s=773+r=001+l=a
http://www.laboratorynetwork.com/doc.mvc/biotime-submits-human-clinical-trials-renevia-europe-0001?atc~c=771+s=773+r=001+l=a
No comments:
Post a Comment